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Women in sub-Saharan Africa are a priority population for evaluation of new biomedical
HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising preven-
tion approach; however, clinical trials among young women using daily or coitally-depen-
dent products have found low adherence. Antiretroviral-containing vaginal microbicide
rings, which release medication over a month or longer, may reduce these adherence
challenges.
Methods
ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, random-
ized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal
ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention
of HIV-1 infection. We describe the baseline characteristics of African women enrolled in
the ASPIRE trial.
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Results
Between August 2012 and June 2014, 5516 women were screened and 2629 HIV-1 sero-
negative women between 18–45 years of age were enrolled from 15 research sites in Ma-
lawi, South Africa, Uganda, and Zimbabwe. The median age was 26 years (IQR 22–31) and
the majority (59%) were unmarried. Nearly 100% of participants reported having a primary
sex partner in the prior three months but 43% did not know the HIV-1 status of their primary
partner; 17% reported additional concurrent partners. Nearly two-thirds (64%) reported hav-
ing disclosed to primary partners about planned vaginal ring use in the trial. Sexually trans-
mitted infections were prevalent: 12% had Chlamydia trachomatis, 7% Trichomonas
vaginalis, 4% Neisseria gonorrhoeae, and 1% syphilis.
Conclusions
African HIV-1 seronegative women at risk of HIV -1 infection were successfully enrolled into
a phase III trial of dapivirine vaginal ring for HIV-1 prevention.
Introduction
Over half of the 24.7 million people living with HIV-1 infection in sub-Saharan Africa in 2013
were women [1]. Unprotected heterosexual intercourse is the leading mode of HIV-1 transmis-
sion amongst women in this region. While a number of HIV-1 prevention interventions have
demonstrated varying effectiveness in reducing HIV-1 risk, including behavior change, use of
male and female condoms, treatment of sexually transmitted infections (STIs), male circumci-
sion, knowledge of HIV-1 status, and uptake of antiretroviral treatment to reduce the infec-
tiousness of persons with HIV-1, HIV-1 rates in young African women in many settings
remain unacceptably high. This is, in part, because many HIV-1 prevention methods require
the participation or consent of a male partner and therefore current prevention options may
prove inadequate for many women, who may be unable to negotiate HIV-1 or STI testing and
treatment or condom use with their partners [2]. Developing woman-controlled HIV-1 pre-
vention options that women can use remains therefore a global priority.
Microbicides are products being developed for topical application inside the vagina or rec-
tum with the intention of reducing the sexual acquisition of HIV-1 and/or other STIs. Vaginal
microbicides offer the promise of a tool to prevent HIV-1 that would be under a woman’s con-
trol and could complement other HIV-1 prevention strategies. Microbicides containing highly
specific HIV-1 antiretroviral medications are one form of HIV-1 pre-exposure prophylaxis
(PrEP), in which a HIV-1 susceptible individual uses oral or topical antiretroviral medications
for prevention of HIV-1 acquisition [3]. Randomized trials of the antiretroviral agent tenofovir,
formulated as oral pills or a topical vaginal gel, demonstrated efficacy in diverse at-risk popula-
tions worldwide [4–8]. However, in two trials among young women at risk for HIV-1 (VOICE
and FEM-PrEP), adherence to daily tenofovir-containing pills or vaginal gels was very low and
HIV-1 prevention efficacy could not be assessed [9–11]. As a result, development of potent, an-
tiretroviral-based prevention products not requiring daily or coitally-dependent adherence has
become a priority.
Vaginal rings have been developed and marketed as delivery methods for medications, capa-
ble of providing sustained and controlled release of active ingredients such as hormonal contra-
ception and estrogen replacement therapy. In recent years, there has been considerable interest
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in developing similar ring devices for the administration of microbicidal compounds to prevent
vaginal acquisition of HIV-1 and other STIs [12]. Intended to be worn continuously, coitally-
independent microbicide rings would in theory maintain effective vaginal microbicide concen-
trations over many weeks or months, thereby addressing challenges around timing of product
application and adherence associated with other prophylaxis strategies. Dapivirine, a substitut-
ed di-amino-pyrimidine derivative with potent activity against HIV-1 as a non-nucleoside re-
verse-transcriptase inhibitor (NNRTI), has been formulated into a silicone elastomer vaginal
microbicide ring. Preclinical studies and multiple early-stage clinical trials have evaluated the
safety of dapivirine in oral, gel, and vaginal ring formulations [13–18]. These clinical trials sup-
port a favourable safety profile and tolerability of dapivirine in general and specifically in vagi-
nal delivery form.
The Microbicide Trials Network (MTN)-020 trial, ASPIRE (A Study to Prevent Infection
with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled
trial evaluating the safety and effectiveness of dapivirine vaginal ring inserted once every four
weeks for the prevention of HIV-1 infection in healthy, HIV-1 uninfected sexually active




Prior to implementation, the study protocol was reviewed and approved by ethics review com-
mittees at collaborating institutions at each of the study sites (National Health Sciences Re-
search Committee of Malawi and Johns Hopkins University Bloomberg School of Public
Health Institutional Review Board [Malawi: Blantyre site], National Health Sciences Research
Committee of Malawi and University of North Carolina at Chapel Hill Institutional Review
Board [Malawi: Lilongwe site], University of Cape Town: Human Research Ethics Committee
[South Africa: Cape Town site], Biomedical Research Ethics Administration, University of
KwaZulu-Natal [South Africa: Durban—eThikwini site], South African Medical Research
Council Ethics Committee [South Africa: Durban—Botha's Hill, Chatsworth, Isipingo, Ton-
gaat, Umkomaas, Verulam sites], Wits Human Research Ethics Committee, University of Wit-
watersrand [South Africa: Johannesburg site], Joint Clinical Research Centre Institutional
Review Board and Johns Hopkins University School of Medicine Institutional Review Board
[Uganda: Kampala site], Medical Research Council of Zimbabwe and Committee on Human
Research, University of California—San Francisco [Zimbabwe: Chitungwiza-Seke South, Chi-
tungwiza-Zengeza, and Harare-Spilhaus sites]) and the Prevention Sciences Review Committee
of the National Institute of Allergy and Infectious Diseases of the US National Institutes of
Health. All participants provided written informed consent.
Study design
ASPIRE is a phase III, multi-site, randomized, double-blind, parallel-arm, placebo-controlled
trial of the dapivirine vaginal ring for the prevention of HIV-1 acquisition in healthy sexually
active HIV-1 uninfected women (ClinicalTrials.gov number NCT01617096). The primary
study objectives are to determine the effectiveness and safety of the dapivirine vaginal ring
when compared against the placebo ring when inserted once every four weeks over the investi-
gational product use period. Secondary objectives include assessment of the acceptability of
and adherence to the dapivirine vaginal ring, the frequency of antiretroviral drug resistance in
women who acquire HIV-1 during the study period, and the relationship between drug
ASPIRE Enrollment
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concentrations and HIV-1 seroconversion. The study protocol can be found at http://www.
mtnstopshiv.org/studies/3614.
The trial was designed with 90% power to detect a minimum 60% reduction in risk of HIV-
1 infection for the primary effectiveness objective, using a log-rank test having a one-sided false
positive error rate of 0.025. A minimum lower bound for the effectiveness of the study product
was set at 25%, consistent with the design of other trials of novel HIV-1 prevention interven-
tions and with a goal of establishing that a novel product has clear public health benefit[19–
21]. Under these assumptions, a minimum of 120 HIV-1 acquisitions events was estimated to
be required. Because an endpoint-driven design was used, the trial will continue until the target
number of HIV-1 endpoints is accrued. Assuming a background HIV-1 incidence of 3.9% per
year (i.e., in the placebo arm), based on HIV-1 incidence in a prior microbicide trial in a similar
population [21] and allowing for a loss to follow-up rate of 1% per month, an initial sample
size of 3476 women was planned. After the trial had initiated, another microbicide trial, con-
ducted at the same or similar study sites, demonstrated a higher than anticipated background
HIV-1 incidence, at over 5% per year [22]. The trial sample size for ASPIRE was then recalcu-
lated to approximately 2600 subjects.
Study procedures
The study is being conducted at fifteen research sites in four African countries: Malawi (Blan-
tyre and Lilongwe), South Africa (Cape Town, Durban [7 sites], Johannesburg), Uganda (Kam-
pala), and Zimbabwe (Chitungwiza [2 sites], Harare). Participants were recruited from a
variety of sources across sites, including clinics for treatment of STIs, family planning clinics,
post-natal clinics, as well as community-based locations. Advice regarding recruitment materi-
als was sought from site community representatives before use.
The trial’s inclusion and exclusion criteria are detailed in Table 1. Enrolled women were as-
signed in a 1:1 ratio to one of the two study arms: to receive either a silicone elastomer vaginal
matrix ring containing 25 mg of dapivirine or a placebo vaginal ring. At this enrollment visit,
women are provided with vaginal ring use instructions by clinical staff and counselled on what
to do in cases of ring expulsion. They then demonstrate the ability to remove and reinsert the
ring. Finally, correct ring placement is assessed by digital exam by clinical staff. The study
product is manufactured by the International Partnership for Microbicides (Silver Spring,
MD). A fixed block size of 12, stratified by site, was used to generate
randomization assignments.
Participants are followed monthly, with HIV-1 counseling and serologic testing, pregnancy
testing, safety monitoring, and product provision. HIV-1 testing is by two HIV-1 rapid tests
(Oraquick, Unigold, or Determine), conducted in parallel and performed at screening, enroll-
ment, and monthly follow-up. During follow-up, a positive result for either (or both) rapid
tests triggers temporary product hold and further evaluation for confirmation of HIV-1 infec-
tion by HIV-1 Western blot and RNA PCR testing. Women with confirmed HIV-1 acquisition
are permanently discontinued from the study product but continue with follow-up; all HIV-1
seroconverters were referred to local services for HIV-1 care and support. Women who become
pregnant are temporarily discontinued from the study product for the duration of pregnancy
and breastfeeding but remain in follow-up. Referrals for pregnancy and HIV-1 care are provid-
ed. Participants will be followed for four weeks after last study product use visit to measure the
potential for delayed HIV-1 seroconversion. Individualized adherence counseling is conducted
at each monthly visit. Returned used rings and quarterly plasma samples are archived for test-
ing for the presence of dapivirine, as objective markers of adherence.
ASPIRE Enrollment
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Table 1. Study Inclusion and Exclusion Criteria.
Inclusion
criteria
Women must meet all of the following criteria to be eligible for inclusion in the study.
1) Age 18 through 45 years (inclusive) at screening,
2) Able and willing to provide written informed consent to be screened for and to take
part in the study
3) Able and willing to provide adequate locator information
4) HIV uninfected based on testing performed at screening and enrollment
5) Per participant report, sexually active, defined as having vaginal intercourse at least
once in the 3 months prior to screening
6) Using an effective method of contraception at enrollment, and intending to use an
effective method for the duration of study participation; effective methods include
hormonal methods (except contraceptive rings); intrauterine device (IUD); and
sterilization (of participant)
7) At screening and enrollment, agrees not to participate in other research studies
involving drugs, medical devices, vaginal products, or vaccines for the duration of study
participation
Note: Tampons may be used for the duration of the trial.
Exclusion
criteria
Women who meet any of the following criteria will be excluded from the study.
1) Per participant report at screening:
a. Intends to become pregnant during study participation
b. Plans to relocate away from the study site during study participation




4) Diagnosed with urinary tract infection (UTI), unless treated and symptoms are
resolved prior to enrollment
5) Diagnosed with pelvic inflammatory disease, an STI or reproductive tract infection
requiring treatment per current WHO guidelines, unless treated and symptoms are
resolved prior to enrollment
6) Has a clinically apparent Grade 2 or higher pelvic exam finding. Cervical bleeding
associated with speculum insertion and/or specimen collection judged to be within the
range of normal is not exclusionary.
7) Participant report and/or clinical evidence of any of the following:
a. Known adverse reaction to any of the study products (ever)
b. Known adverse reaction to latex (ever)
c. Chronic vaginal candidiasis
d. Non-therapeutic injection drug use in the 12 months prior to Screening
e. Post-exposure prophylaxis (PEP) for HIV-1 exposure within 6 months prior to
enrollment
f. Last pregnancy outcome 90 days or less prior to enrollment
g. Gynaecologic or genital procedure (e.g., tubal ligation, dilation and curettage,
piercing) 90 days or less prior to enrollment
h. Participation in any other research study involving drugs, medical devices, vaginal
products, or vaccines, within 60 days of enrollment
i. Participation in any HIV prevention study using systemic or topical antiretroviral
medications, within 12 months of enrollment
j. As determined by the site investigator, any significant uncontrolled active or chronic
cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric,
endocrine, respiratory, immunologic disorder or infectious disease, including active
tuberculosis
8) Has any of the following laboratory abnormalities at Screening Visit:
(Continued)
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All participants receive a package of HIV-1 prevention services at each study visit, including
HIV-1 and STI risk reduction counselling and free condoms. Etiologic testing and treatment
for STIs for participants and partner (where possible) was done at screening and during fol-
low-up, including for syphilis (rapid plasma reagin [RPR] screening test followed by a confir-
matory microhemagglutinin assay for Treponema pallidum [MHA-TP] or Treponema
pallidum haemagglutination assay [TPHA] for reactive samples), Neisseria gonorrhoeae and
Chlamydia trachomatis (the Becton Dickenson Probe Tec strand displacement assay, and
Trichomonas vaginalis (OSOM Rapid Trichomonas test); treatment was provided on site. Con-
traception was provided free-of-charge at each research site, and all sites were encouraged to
offer a broad mix of methods.
Site staff entered demographic, behavioural, and clinical data related to screening and en-
rollment onto standard paper-based case report forms. Each form was faxed using DataFax
software (DF/Net Software ULC) and received at the Statistical and Data Management Center
located in Seattle, Washington, USA. Two independent data technicians verified the data on
each form. Audio computer assisted self-interview (ACASI) was also used for behavioural data
collection. ACASI data were transmitted electronically and securely to the trial’s data manage-
ment center. Data analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Between August 2012 and June 2014, 5516 women were screened for study eligibility and 2629
were enrolled, with a screen-to-enroll ratio of 2.1:1. Fifty-four percent of those enrolled were
from South Africa, with 10% each fromMalawi and Uganda, and 26% from Zimbabwe
(Table 2). Women’s ages spanned the full extent of the eligibility age range, from 18 to 45
years, with a median age of 26 years (interquartile range [IQR] 22–31), 39%<25 years of age
and 14%35 years of age. Most participants from the South African sites were unmarried
(92%) compared to Uganda (34%), Malawi (15%), and Zimbabwe (17%), and 85% of all en-
rolled participants completed some secondary schooling or higher.
Nearly 100% of participants reported having a primary sex partner during the 3 months
prior to trial enrollment, and 17% reported additional partners in this period. The median
number of sex acts during the 3 months prior to trial enrollment was 20 (IQR 7–36), and 57%
reported male or female condom use with the last vaginal sex act. Anal sex in these prior three
Table 1. (Continued)
a. Aspartate aminotransferase (AST) or alanine transaminase (ALT) Grade 1 or
higher
b. Creatinine Grade 2 or higher
c. Hemoglobin Grade 2 or higher
d. Platelet count Grade 1 or higher
e. Pap result Grade 2 or higher
9) Has any other condition that, in the opinion of the site investigator, would preclude
informed consent, make study participation unsafe, complicate interpretation of study
outcome data, or otherwise interfere with achieving the study objectives
Note: Grading of clinical and laboratory abnormalities is defined per the National Institute of Allergy and
Infectious Diseases Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
Version 1.0, December, 2004 (Clarification dated August 2009) and the Female Genital Grading Table for
Use in Microbicide Studies Addendum 1 to the Division of AIDS Table for Grading Adult and Pediatric
Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009)
doi:10.1371/journal.pone.0128857.t001
ASPIRE Enrollment
PLOS ONE | DOI:10.1371/journal.pone.0128857 June 10, 2015 6 / 12





Participants enrolled, N 272 1426 253 678 2629
Age, years (median, IQR) 28 (24,
33)
24 (21, 29) 28 (24,
33)
28 (25, 33) 26 (22, 31)
Currently unmarried 41 (15%) 1313
(92%)
87 (34%) 112 (17%) 1553 (59%)
Highest level of education
No schooling 9 (3%) 3 (0.2%) 9 (4%) 2 (0.3%) 23 (1%)
Primary school (partial and complete) 140
(51%)
46 (3%) 117 (46%) 78(12%) 381 (14%)




112 (44%) 592 (87%) 2070 (79%)
Attended college or university 2 (1%) 132 (9%) 15 (6%) 6 (1%) 155 (6%)






673 (99%) 2616 (100%)





135 (53%) 585 (86%) 2190 (83%)
1 12 (4%) 180 (13%) 72 (28%) 40 (6%) 304 (12%)
2 or more 9 (3%) 27 (2%) 46 (18%) 53 (8%) 135 (5%)
Number of vaginal sex acts in the past 3 months (median, IQR) 36 (16,
48)
10 (5, 20) 12 (6, 30) 48 (36, 70) 20 (7, 36)
Type of condom used in the last act of vaginal sex
Male condom 103
(38%)
944 (66%) 80 (32%) 347 (51%) 1474 (56%)
Female condom 1 (0.4%) 14 (1%) 2 (1%) 10 (1%) 27 (1%)
Neither 167
(61%)
463 (32%) 169 (67%) 321 (47%) 1120 (43%)
Anal sex in the past 3 months 2 (1%) 43 (3%) 5 (2%) 4 (1%) 54 (2%)
In past year, received money, material goods, gifts, drugs or shelter in
exchange for vaginal or anal sex
16 (6%) 88 (6%) 38 (15%) 21 (3%) 163 (6%)




76 (30%) 629 (93%) 1972 (75%)
Primary partner knows has been asked to use ring 249
(92%)
807 (57%) 48 (19%) 576 (86%) 1680 (64%)
Primary partner HIV status
HIV positive 4 (1%) 16 (1%) 2 (1%) 13 (2%) 35 (1%)
HIV negative 196
(72%)
928 (65%) 113 (45%) 207 (31%) 1444 (55%)
Participant does not know 71 (26%) 476 (34%) 137 (54%) 453 (67%) 1137 (43%)




220 (87%) 657 (98%) 2538 (97%)
Current method of contraception
Intrauterine device 6 (2%) 79 (6%) 71 (28%) 169 (25%) 325 (12%)





112 (44%) 179 (26%) 1452 (55%)







Norethisterone enanthate (NET-EN) 0 (0%) 380 (36%) 0 (0%) 0 (0%) 380 (26%)
(Continued)
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months was reported by 2% of those enrolled (n = 54), and transactional sex in the past year
was reported by 6%
Out of 2616 participants reporting a primary sex partner in the past 3 months, 1.3%
(n = 35) knew their primary partner was HIV-1 infected while 43% did not know their primary
partner’s HIV-1 serostatus. Seventy-five percent of participants reported that their primary
partner was aware of their participation in the research study, but this level of disclosure varied
across the countries from 95% in Malawi to 30% in Uganda. Sixty-four percent reported that
their primary partner knew that they would be using a vaginal ring, from 92% in Malawi to
19% in Uganda
Baseline contraceptive use reflects a wide method mix: 55% of women reported use of in-
jectable contraception with the majority of those (74%) using injectable depot medroxyproges-
terone acetate and 26% injectable norethisterone enanthate, 11% used combined oral
contraceptives, 12% intrauterine devices, and 19% contraceptive implants (Table 2).
The most common STI detected at the screening visit was C. trachomatis, found in 12% of
the cohort and with the highest prevalence reported at the South African sites (17%). This was
followed by T. vaginalis in 7%, N. gonorrhoeae in 4%, and syphilis in 1% of participants.
Of 5516 women screened, 2887 (52%) did not enroll (Table 3), of whom 2454 completed
screening but were not eligible and 378 did not complete screening. Only 55 women (1% of
those screened) were eligible but declined enrollment. Among the 2454 ineligible women, the
most common reason was seropositivity for HIV-1 (35%, 854 women). Other reasons included
pregnancy or planning to become pregnant (8%, 203 women), breastfeeding (1%, 31 women),
not meeting laboratory eligibility criteria (8%, 203 women), and not meeting other clinical eli-
gibility criteria (12%, 295 women). Only 58 (2%) of women were ineligible based on a grade 2
or higher pelvic examination finding. Finally, site investigators exercised discretion to exclude
potential subjects for whom study participation would be unsafe or whose participation would
complicate interpretation of study outcome data or otherwise interfere with achieving the
study objectives. This discretion was exercised for 753 women (31% of those screened and not
enrolled). Most often, this discretion was used to enroll women committed to the study objec-








21 (1%) 49 (19%) 311 (46%) 501 (19%)
Sterilization 25 (9%) 42 (3%) 7 (3%) 3 (0.4%) 77 (3%)
STIs detected at the screening visit
Trichomonas vaginalis 28 (10%) 88 (6%) 13 (5%) 51 (8%) 180 (7%)
Neisseria gonorrhoeae 13 (5%) 55 (4%) 15 (6%) 26 (4%) 109 (4%)
Chlamydia trachomatis 6 (2%) 237 (17%) 25 (10%) 48 (7%) 316 (12%)
Syphilis2 11 (4%) 7 (0.5%) 6 (2%) 15 (2%) 39 (1%)
1Note that the denominators used to calculate percentages throughout this table may vary owing to small amounts of missing data for individual variables
and may not sum to 100% due to rounding.
2 Based on a reactive result to the syphilis screening and a positive confirmatory test result. Note that participants testing positive at screening were
provided treatment according to WHO guidelines.
doi:10.1371/journal.pone.0128857.t002
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Discussion
African HIV-1 seronegative women at risk of HIV-1 acquisition from the general population
were successfully enrolled into this phase III trial of the dapivirine vaginal ring for HIV-1 pre-
vention. Participants were sexually active, with an important minority reporting>1 partner
during the prior 3 months, and curable STI prevalence was high. The accrual of women for this
study demonstrates the feasibility of identifying and recruiting women to determine the effec-
tiveness and safety of the dapivirine vaginal ring as PrEP, and indicates that HIV-1 seronega-
tive women are readily identifiable in peri-urban and urban settings in sub-Saharan Africa for
targeted implementation and delivery of this microbicide, if demonstrated to be efficacious and
safe for HIV-1 prevention.
CAPRISA 004, a study of pericoital vaginal use of a 1% tenofovir gel, demonstrated the effi-
cacy of vaginal tenofovir gel for the prevention of HIV-1 acquisition by women in South Africa,
providing the first proof-of-concept for the use of a topical microbicide [4]. This finding was
followed closely by evidence of the efficacy of oral tenofovir-based PrEP in men who have sex
with men and heterosexual men and women [4–8]. In these trials, HIV-1 protection was
strongly correlated with PrEP adherence. In two additional trials of tenofovir-based PrEP, eval-
uating gel and oral formulations, efficacy was not seen and testing of participant blood samples
revealed only a minority (<30%) were using the study products consistently [9,11,22]. These
findings underscore the importance of adherence to oral and topical PrEP and for evaluating
new PrEP strategies; the continuous dosing regimen provided by the dapivirine ring may ad-
dress at least in part- address PrEP adherence challenges. Notably, in the ASPIRE population,










678 (55%) 2629 (48%)




560 (45%) 2887 (52%)
Participant did not complete all screening procedures 0 (0%) 279 (8%) 31 (8%) 68 (6%) 378 (7%)
Participant is eligible but declined enrollment 1 (<1%) 35 (1%) 4 (1%) 15 (1%) 55 (1%)




477 (39%) 2454 (44%)
Participant < 18 or > 45 years old 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Plans for relocation/travel 8 (6%) 37 (2%) 5 (4%) 18 (4%) 68 (3%)
Participant is pregnant or planning to become pregnant 9 (7%) 108 (6%) 18 (15%) 68 (14%) 203 (8%)
Participant is breastfeeding 5 (4%) 22 (1%) 2 (2%) 2 (<1%) 31 (1%)
Participant has not had vaginal sex in the last 3 months 5 (4%) 41 (2%) 3 (3%) 7 (1%) 56 (2%)
Participant has enrolled in another research study in the last 60 days 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Participant has participated in VOICE or other HIV prevention trial in the past
12 months
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
PEP exposure in the last 6 months 2 (2%) 4 (<1%) 0 (0%) 0 (0%) 6 (<1%)
Participant is HIV-positive 19 (15%) 590 (34%) 27 (23%) 218 (46%) 854 (35%)
Participant declines effective method of contraception 5 (4%) 15 (1%) 6 (5%) 1 (<1%) 27 (1%)
Participant has a grade 2 or higher pelvic exam finding 3 (2%) 43 (2%) 2 (2%) 10 (2%) 58 (2%)
Participant does not meet laboratory eligibility criteria 8 (6%) 159 (9%) 9 (8%) 27 (6%) 203 (8%)
Participant does not meet other clinical eligibility criteria 6 (5%) 225 (13%) 6 (5%) 58 (12%) 295 (12%)
Other reason, including investigator decision 60 (48%) 553 (32%) 51 (43%) 89 (19%) 753 (31%)
doi:10.1371/journal.pone.0128857.t003
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approximately 40% of participants were less than 25 years of age at the time of enrollment,
more than half were unmarried (59%), and over 40% reported recent sex unprotected by con-
doms. In the VOICE trial of HIV-1 seronegative heterosexual women, these baseline character-
istics predicted higher HIV-1 incidence as well as lower product adherence [22].
In prior PrEP studies, multiple methods were used to assess adherence, including self-re-
port, counts of returned unused pills or gel applicators, and audio computer-assisted self-inter-
view. Nonetheless, in several of these studies, fewer than half of all participants disclosed non-
adherence or barriers to use, and products were returned in a manner consistent with high
product use [22]. These findings support the need for measures of product adherence that do
not rely solely on self-report or are easily manipulated by participants. In the ASPIRE study,
plasma samples and returned used rings are collected for dapivirine testing and will provide an
objective marker of product adherence.
All participants in ASPIRE receive a comprehensive package of HIV-1 risk reduction ser-
vices, including condoms, counselling about risk reduction, STI diagnosis and treatment, offers
for partner testing, and referrals for further care throughout study follow-up. Although self-re-
ported condom use for last vaginal sex act at baseline was high in our cohort (57%), women
may have over-reported condom use as a result of social desirability bias. Although condoms
have proven efficacy, their effectiveness is limited due to inconsistent and incorrect use [23].
Moreover, condom use may be outside of the locus of female control, antithetical to constructs
of trust and love and mediated by transactional exchanges of gifts or cash [24]. As female-initi-
ated methods, microbicides are positioned to reduce women’s vulnerability to HIV-1 infection
by empowering women to control their use [25,26]. High HIV-1 prevalence at screening across
the study countries underscores the urgency around identification of interventions for women
to protect themselves from HIV-1 acquisition.
One of the defining characteristics of microbicides has been its potential to be used clandes-
tinely, or without the explicit acquiescence of a male partner. Interestingly, however, the major-
ity of women in ASPIRE report telling their male partners about their planned study
participation and anticipated ring use. Additional work during the trial will explore disclosure
of ring use, male partners’ perceived attitudes and reactions, and the influence of male partners
on women’s adherence to ring use.
Many factors, aside from susceptibility to HIV-1 infection, motivate young women to enroll
into HIV-1 prevention clinical trials. Perceived access to quality health services including HIV-
1 counselling and testing, health education, transportation reimbursement, peer pressure and
altruism are all cited as motivators for study participation [27]. Given the long duration of
HIV-1 prevention trials, participants’ life circumstances often change over time and consider-
ation for management of commitment to visit schedules may be explored in advance of enroll-
ment in the context of life plans (e.g. potential future employment, education or marriage).
Careful assessment of all women presenting for enrollment by site investigators during the
screening process was encouraged and executed across ASPIRE sites in an attempt to recruit
individuals committed for the duration of the study.
Approximately 20% of women who screened out were due to clinical and laboratory related
eligibility criteria. If dapivirine-based PrEP is shown to be safe and efficacious in ongoing trials,
its safety will subsequently need to be assessed in HIV-1 susceptible persons who are less opti-
mally healthy than those selected for this trial, as well as pregnant and lactating women. Bridg-
ing studies are already being planned for lactating women to respond to these questions.
Participants in prevention research on stigmatized diseases such as HIV/AIDS face social
and psychological risks, especially marginalized and vulnerable populations [28,29]. However,
our results demonstrate that a cohort of 2629 African heterosexual women at risk of HIV-1
transmission was successfully recruited into a placebo-controlled safety and effectiveness trial
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of the dapivirine vaginal ring. If this microbicide is demonstrated to be safe and effective in AS-
PIRE and a second ongoing phase III trial (The Ring Study), implementation of this interven-
tion could be targeted to at-risk women in an effort to curb the HIV epidemic. For persons at
ongoing risk of HIV-1 infection, topical and oral antiretroviral prophylaxis provides a time-
limited HIV-1 prevention strategy under their control. As with all prevention strategies, PrEP
is only effective if used, and maximum PrEP benefits, at both individual and population levels,
will likely be achieved by combining PrEP with other effective HIV-1 prevention interventions.
Long-acting microbicide-based PrEP products, if found to be well tolerated and effective, could
simplify dosing regimens, thereby reducing user- dependent adherence challenges. A monthly
vaginal ring may offer women a novel prevention strategy that will allow for effective preven-
tion of HIV-1 acquisition.
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